Orchestra BioMed
OBIO
Orchestra BioMed (OBIO) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.50
- EPS estimate
- −$0.50
- EPS surprise
- +0.04%
- Revenue surprise
- +7.34%
- Revenue
- $836,000.00
- Revenue estimate
- $778,833.00
- Reported
- Aug 12, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 12, 2025 | −$0.50 | −$0.50 | +0.04% | $836,000.00 | SEC |
| Q1 2025 | May 12, 2025 | −$0.48 | −$0.49 | −2.08% | $868,000.00 | SEC |
| Q4 2024 | Mar 31, 2025 | −$0.43 | −$0.42 | +1.45% | $253,000.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.43 | −$0.41 | +4.65% | $987,000.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.39 | −$0.45 | −14.65% | $778,000.00 | SEC |
| Q1 2024 | May 13, 2024 | −$0.40 | −$0.38 | +4.28% | $620,000.00 | SEC |
| Q4 2023 | Mar 27, 2024 | −$0.38 | −$0.35 | +7.04% | $262,000.00 | SEC |
| Q3 2023 | Nov 13, 2023 | −$0.39 | −$0.38 | +2.56% | $419,000.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$0.42 | −$0.35 | +15.66% | $915,000.00 | SEC |
| Q1 2023 | May 12, 2023 | −$0.29 | −$0.40 | −40.35% | $1.2M | SEC |
Quarterly revenue
Frequently asked questions
When did Orchestra BioMed (OBIO) last report earnings?
Orchestra BioMed last reported on Aug 12, 2025, covering fiscal Q2 2025.
Did OBIO beat earnings estimates?
Yes. Orchestra BioMed reported EPS of −$0.50 for Q2 2025 against a −$0.50 estimate — a 0.04% beat.
How much revenue did OBIO report last quarter?
Orchestra BioMed reported $836,000.00 in revenue for Q2 2025, against a consensus estimate of $778,833.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.